rformance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

References

1Tricou, V. Efficacy and Safety of Takeda’s Tetravalent Dengue Vaccine Candidate (TAK-003) After 4.5 Years of Follow-Up. Presented at the 8 Northern European Conference of Travel Medicine; June 2022.
2Escudero, I. Evaluation of a Booster Dose of the Tetravalent Dengue Vaccine, TAK-003, in Healthy Children in De
=*=*=*=*=*=
当前为第19/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页